Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine

Transplantation
R B Goldberg, D Roth

Abstract

Occlusive atherosclerosis is a major cause of morbidity and mortality in renal transplant recipients. Hyperlipidemia associated with the transplanted state may be at least partially responsible for this complication and is therefore an important target of therapy. The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are powerful cholesterol-lowering drugs, but their broad use in transplant recipients has been hindered by concerns about interactions with cyclosporine. Cyclosporine interferes with the elimination of these agents, increasing their plasma and tissue levels and predisposing the patient to rhabdomyolysis. Fluvastatin, the first entirely synthetic HMG-CoA reductase inhibitor, possesses a distinct pharmacologic profile, including a shorter half-life and virtually no active circulating metabolites. Therefore, it may interact differently with cyclosporine. The pharmacokinetics and safety of fluvastatin, 20 mg/day, were evaluated in 20 hypercholesterolemic renal transplant recipients also receiving cyclosporine, usually in combination with azathioprine and methylprednisolone, during the 14-week study. Fluvastatin area under the curve, maximum plasma concentration, and time to maximum plasma concentrati...Continue Reading

References

Jun 1, 1992·Journal of the American Society of Nephrology : JASN·J D PirschF O Belzer
Feb 1, 1992·The Annals of Pharmacotherapy·C S Wallace, B A Mueller
Nov 1, 1990·Circulation·S G Young
Sep 1, 1989·The American Journal of the Medical Sciences·G Ferenchick, D Rovner
Nov 11, 1988·The American Journal of Cardiology·J A Tobert
Jan 7, 1988·The New England Journal of Medicine·D J NormanJ Hosenpud
Jan 7, 1988·The New England Journal of Medicine·C EastJ A Farmer
Jan 1, 1987·Medical Toxicology·L C Knodel, R L Talbert
May 16, 1985·The New England Journal of Medicine·E J Schaefer, R I Levy
Jun 6, 1994·The American Journal of Medicine·M H Davidson
Apr 1, 1994·Annals of Internal Medicine·D L SprecherL Jokubaitis

❮ Previous
Next ❯

Citations

Jul 31, 2009·European Journal of Clinical Pharmacology·Hanna Marita SeidlingWalter Emil Haefeli
Aug 13, 2003·Current Atherosclerosis Reports·Ulrich Laufs, James K Liao
Dec 20, 2000·Transplantation Proceedings·C K Tan
Feb 9, 2000·Pharmacology & Therapeutics·A CorsiniF Bernini
Jun 27, 2000·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·C M Ballantyne
Jun 5, 2002·Atherosclerosis. Supplements·Rodolfo PaolettiStefano Bellosta
Jul 21, 1999·Kidney International. Supplement·A Martínez-CastelaoJ Alsina
Dec 11, 2002·Kidney International·G V Ramesh PrasadJeffrey S Zaltzman
May 24, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Wolf DrescherFrank Eitner
Apr 12, 2005·Annual Review of Pharmacology and Toxicology·Yoshihisa ShitaraYuichi Sugiyama
Feb 28, 2002·Journal of Clinical Pharmacology·S Appel-DingemanseM Merz
Oct 16, 2001·Drugs & Aging·B TomlinsonW Lan
May 23, 2001·Clinical Pharmacokinetics·C D Scripture, J A Pieper
Jun 18, 2004·Drugs·Alberto CorsiniChristie M Ballantyne
Jun 30, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Hallvard Holdaas
Jan 29, 2000·Journal of Clinical Pharmacy and Therapeutics·A Jardine, H Holdaas
Aug 16, 2006·Expert Opinion on Drug Safety·Atul TiwariKasim Mookhtiar
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Dec 24, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jennifer Martin, Henry Krum
Jan 10, 2001·The American Journal of the Medical Sciences·M KususA W Dreisbach
Oct 29, 2011·Clinics in Liver Disease·R Todd StravitzDiane M Biskobing
Oct 13, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·G V Ramesh PrasadCarl J Cardella
Mar 19, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·B KasiskeUNKNOWN National Kidney Foundation
Nov 26, 2009·Chemistry & Biodiversity·Christopher Kohl
Jan 16, 2007·Alimentary Pharmacology & Therapeutics·A Sethi, R T Stravitz
Nov 3, 2004·Transplantation Proceedings·T TokumotoH Toma
Apr 30, 2005·International Journal of Cardiology·Vincent Launay-VacherGilbert Deray
Sep 8, 2004·Expert Review of Cardiovascular Therapy·Anders Asberg, Hallvard Holdaas
Mar 22, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·J W ParkW Jaross
Mar 7, 2018·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Jan 20, 2005·Circulation·Robert L PageJoAnn Lindenfeld
Jul 20, 2002·Clinical Pharmacokinetics·Fatemeh Akhlaghi, Andrew K Trull
Mar 3, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Yi-An BiYurong Lai
Jul 9, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A AsbergH Holdaas

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.